12:00 AM
Mar 09, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Toremifene citrate regulatory update

GTx said FDA gave an NDA for toremifene 80 mg to prevent bone fractures in men with prostate cancer on androgen deprivation therapy a...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >